Perspective Therapeutics (CATX)

Executive Summary

Perspective Therapeutics is a clinical-stage radiopharmaceutical company focused on targeted alpha-particle therapy (TAT) using its proprietary lead-212 (Pb-212) platform. Formed in 2023 from the merger of Viewpoint Molecular Targeting and Isoray, the company leverages chemically matched lead isotope pairs (Pb-203 for imaging, Pb-212 for therapy) to deliver tumor-selective radiation. Its pipeline targets multiple solid tumors and hematologic malignancies, with lead programs in neuroendocrine tumors, melanoma, and pancreatic cancer. The platform's theranostic approach enables real-time imaging and dosimetry, potentially improving treatment precision and patient outcomes. Perspective's most advanced candidate, VMT-α-NET (targeting somatostatin receptor 2), is in Phase 1/2 trials for neuroendocrine tumors, with a Phase 1 study (NCT05111509) expected to complete in mid-2026. The company is also evaluating VMT01 (targeting MC1R) in melanoma combined with nivolumab, and PSV359 (targeting a novel cancer antigen) in multiple solid tumors. Early clinical data have shown encouraging safety and efficacy signals. With a robust pipeline and a differentiated alpha-emitter platform, Perspective Therapeutics has the potential to address significant unmet needs in oncology.

Upcoming Catalysts (preview)

• Q2 2026Top-line data from Phase 1 [203Pb]VMT-α-NET monotherapy trial (NCT05111509)80% success
• Q3 2026Interim data from Phase 1/2 [203/212Pb]VMT-α-NET trial (NCT05636618) at a medical conference60% success
• Q4 2026Initial safety/imaging data from Phase 1/2 [212Pb]Pb-PSV359 trial (NCT06710756)50% success